Literature DB >> 11334453

Failure of bipolar hemiarthroplasty: a retrospective review of 31 consecutive bipolar prostheses converted to total hip arthroplasty.

S H Coleman1, M Bansal, C N Cornell, T P Sculco.   

Abstract

Bipolar hemiarthroplasty has been widely used for the treatment of femoral neck fractures in elderly patients. Outcome studies show excellent results with near preoperative ambulation and lasting, painless hip function. However, what has only recently been considered is that, in some cases, failure of bipolar hemiarthroplasty may be due to wear of the thin, ultra-high-molecular weight polyethylene (UHMWPE) insert between the inner and outer bearings of the prosthesis with subsequent generation of particulate debris, periprosthetic osteolysis, and stem loos ening. We reviewed 31 consecutive bipolar hemiarthroplasties converted to total hip arthroplasties by a single surgeon between 1986 and 1994. The average time to failure was 38 months. Fifty-six percent of the cases showed radiographic evidence of osteolysis around the stem. Radiographic migration of the bipolar head of more than 1 mm into the pelvis, suggestive of cartilage wear, occurred in 67% of the cases. Among the patients with radiographic osteolysis and a loose stem at the time of revision, 92% showed a characteristic histiocytic and giant cell reaction to polyethylene particles in tissue obtained during surgery. The UHMWPE liners from the retrieved outer shells showed an average wear rate of 0.7 mm per year. Recent studies comparing bipolar to unipolar hemiarthroplasty show little difference between the two with regard to morbidity, mortality, or functional outcome. In light of our findings, it might be prudent to reconsider the design and indications for bipolar hemiarthroplasty.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334453

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  7 in total

1.  Comparison of Minimally Invasive Total Hip Arthroplasty versus Conventional Hemiarthroplasty for Displaced Femoral Neck Fractures in Active Elderly Patients.

Authors:  Kyung-Soon Park; Chang-Seon Oh; Taek-Rim Yoon
Journal:  Chonnam Med J       Date:  2013-08-22

2.  Treatment of femoral neck fractures in elderly patients over 60 years of age - which is the ideal modality of primary joint replacement?

Authors:  Christian Ossendorf; Max J Scheyerer; Guido A Wanner; Hans-Peter Simmen; Clément Ml Werner
Journal:  Patient Saf Surg       Date:  2010-10-20

3.  Disorder-related risk factors for revision total hip arthroplasty after hip hemiarthroplasty in displaced femoral neck fracture patients: a nationwide population-based cohort study.

Authors:  Chun-Hao Tsai; Chih-Hsin Muo; Chih-Hung Hung; Tsung-Li Lin; Ta-Ii Wang; Yi-Chin Fong; Horng-Chaung Hsu
Journal:  J Orthop Surg Res       Date:  2016-06-08       Impact factor: 2.359

4.  Is bipolar hemiarthroplasty an appropriate type of hip articulation following proximal femoral or total femoral resections for musculoskeletal malignancies?

Authors:  Fevzi Saglam; Ozgur Baysal; Evrim Sirin; Omer Sofulu; Mehmet Deniz Kesimer; Bulent Erol
Journal:  Arch Orthop Trauma Surg       Date:  2021-06-06       Impact factor: 3.067

5.  Hemiarthroplasties in young patients with osteonecrosis or a tumour of the proximal femur; an observational cohort study.

Authors:  Pim W van Egmond; Antonie H M Taminiau; Huub J L van der Heide
Journal:  BMC Musculoskelet Disord       Date:  2013-01-17       Impact factor: 2.362

6.  Midterm Results of Conversion from Failed Bipolar Hemiarthroplasty to Total Hip Arthroplasty.

Authors:  Kyung-Soon Park; Chee-Ken Chan; Dong-Hyun Lee; Taek-Rim Yoon
Journal:  Indian J Orthop       Date:  2018 Jul-Aug       Impact factor: 1.251

7.  Interventions for treating displaced intracapsular femoral neck fractures in the elderly: a Bayesian network meta-analysis of randomized controlled trials.

Authors:  Bin-Fei Zhang; Peng-Fei Wang; Hai Huang; Yu-Xuan Cong; Hu Wang; Yan Zhuang
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.